Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine plus imatinib versus imatinib alone in chronic myeloid leukemia with residual molecular disease
2009-014373-41Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Imatinib alone with Hydroxychloroquine + imatinib (2 arms). Primary endpoint: Withdrawal or dose-escalation handling. Started Mar 2010; status: completed.
02
Drugs
hydroxychloroquineimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2009-014373-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014373-41.